Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support ...
Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...
From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree
While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results